Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OP-1250 in Advanced HR+/HER2- Breast Cancer
NCT04505826Phase 2Completed
- Sponsor
- Olema Oncology
- Start
- Aug 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of palazestrant in breast cancer, sponsored by Olema Oncology. Started Aug 2020; status: completed.
02
Drugs
palazestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04505826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04505826.